Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer progression often involves dependence on growth factor signaling pathways, including c-Src.
• c-Src is implicated in tumor cell proliferation, migration, and invasion, making it a potential therapeutic target.
• Targeting c-Src may offer a strategy to prevent prostate tumor spreading.

Purpose of the Study:

• To investigate the role of c-Src in the aggressive phenotype of prostate carcinoma PC3 cells.
• To evaluate the efficacy of novel pyrazolo[3,4-d]pyrimidines, SI35 and SI40, as c-Src inhibitors.
• To determine the impact of these inhibitors on PC3 cell proliferation, migration, and morphology.

Main Methods:

• Utilized PC3 prostate carcinoma cell line.
• Administered novel pyrazolo[3,4-d]pyrimidines (SI35, SI40) targeting c-Src.
• Assessed cell proliferation, migratory ability upon epidermal growth factor (EGF) stimulation, cell morphology, and adhesion.
• Analyzed downstream signaling pathways including paxillin and extracellular signal-regulated kinase (ERK).

Main Results:

• SI35 and SI40 reduced PC3 cell proliferation in a dose- and time-dependent manner (IC50 ~50 microM).
• SI molecules significantly inhibited EGF-induced PC3 cell migration.
• These inhibitors modulated cell morphology and adhesion to physiological substrates.
• SI treatment led to down-modulation of active paxillin and ERK, alongside c-Src inhibition.

Conclusions:

• Pyrazolo[3,4-d]pyrimidines targeting c-Src demonstrate potent anti-proliferative and anti-migratory effects on prostate cancer cells.
• These compounds modulate key signaling molecules involved in cell invasion and adhesion.
• Novel pyrazolo[3,4-d]pyrimidines represent a promising therapeutic strategy for controlling aggressive prostate carcinoma phenotypes.